Therefore, combined treatment with CB-839/telaglenastat (GLS1 inhibitor) plus metformin can effectively suppress ESCC cell proliferation in vitro and xenograft growth in vivo [51]. This evidence concerns the gene GLS and esophageal squamous cell carcinoma.